Rigel Pharmaceuticals, Inc. (RIGL) News
Filter RIGL News Items
RIGL News Results
|Loading, please wait...|
RIGL News Highlights
- RIGL's 30 day story count now stands at 8.
- Over the past 17 days, the trend for RIGL's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- CVAC, LUNG and MRNA are the most mentioned tickers in articles about RIGL.
Latest RIGL News From Around the Web
Below are the latest news stories about Rigel Pharmaceuticals Inc that investors may wish to consider to help them evaluate RIGL as an investment opportunity.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in September:
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clinical Infectious Diseases, an official publication of the Infectious Disease Society of America. The study was sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System.
Rigel Pharmaceuticals (NASDAQ: RIGL) recently received a thumbs-down from the Food and Drug Administration for an EUA filing for its COVID therapeutic candidate. In this Motley Fool Live video recorded on Aug. 18, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why the FDA turned down an EUA for Rigel's experimental COVID therapy.
Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rigel Pharmaceuticals, Inc. - RIGL
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") (NASDAQ: RIGL). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The
Rigel Pharmaceuticals' (RIGL) fostamatinib does not get the FDA's nod for emergency use for COVID-19. The company plans to submit data from a larger study.
The FDA has informed Rigel Pharmaceuticals Inc (NASDAQ: RIGL ) that data submitted in May from fostamatinib Phase 2 trial
(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) said Friday that the U.S. Food and Drug Administration did not issue emergency use authorization for fostamatinib for the treatment of COVID-19 in hospitalized adults, due to insufficient clinical data. In Friday pre-market trade, RIGL was trading at $3.60, down $0.53 or 12.83%. "The FDA has
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib to treat hospitalized patients suffering from COVID-19 are insufficient for an emergency use authorization (EUA) at this time. The FDA noted in their response that they remain committed to working with Rigel in the development of fostamatinib for COVID-19 a
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.